¸Á¸·Á¤¸ÆÆó¼âÁõ Ä¡·á ½ÃÀå ±Ô¸ð, Á¡À¯À², ¼ºÀå ºÐ¼® : Áúȯ À¯Çüº°, Ä¡·á À¯Çüº°, Åõ¾à À¯Çüº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° - »ê¾÷ ¿¹Ãø(2025-2032³â)
Retinal Vein Occlusion Treatment Market Size, Share, and Growth Analysis, By Disease Type (Central Retinal Vein Occlusion, Branch Retinal Vein Occlusion ), By Treatment Type, By Medication Type, By End-user, By Region - Industry Forecast 2025-2032
¸Á¸·Á¤¸ÆÆó¼âÁõ Ä¡·áÁ¦ ½ÃÀå ±Ô¸ð´Â 2023³â 24¾ï 3,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. 2024³â 25¾ï 9,000¸¸ ´Þ·¯¿¡¼ 2032³â¿¡´Â 42¾ï 5,000¸¸ ´Þ·¯·Î È®´ëµÉ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ¿¹Ãø ±â°£(2025-2032³â) µ¿¾È 6.4%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» º¸ÀÏ Àü¸ÁÀÔ´Ï´Ù.
¸Á¸·Á¤¸ÆÆó¼âÁõ(RVO) Ä¡·á ½ÃÀåÀº RVOÀÇ À¯º´·ü Áõ°¡¿Í ÀÌ Áúȯ¿¡ Ãë¾àÇÑ Àα¸ÀÇ °í·ÉÈ¿¡ ÈûÀÔ¾î Å©°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ¸Á¸·Ç÷°üÁúȯ Áß ÇϳªÀÎ RVO´Â Ä¡·áÇÏÁö ¾ÊÀ¸¸é ½Ã·Â Àå¾Ö¸¦ ÃÊ·¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ½ÃÀå¿¡¼´Â ¾à¹° ¿ä¹ý, ·¹ÀÌÀú ¿ä¹ý, ¼ö¼ú ¿ä¹ý µî ÁÖ·Î Ç÷¾×¼øÈ¯ °³¼±°ú Ȳ¹ÝºÎÁ¾ ¿ÏÈ¿¡ ÁßÁ¡À» µÐ ´Ù¾çÇÑ ¼Ö·ç¼ÇÀÌ Á¦°øµÇ°í ÀÖ½À´Ï´Ù. Ç×VEGF ¾à¹°Àº ºñÁ¤»óÀûÀÎ Ç÷°ü ¹ß´ÞÀ» °ü¸®Çϱâ À§ÇØ Æ¯È÷ ¼±È£µÇ°í ÀÖ½À´Ï´Ù. ºÏ¹Ì¿Í À¯·´°ú °°Àº Áö¿ªÀº ¼±ÁøÈµÈ ÀÇ·á ½Ã½ºÅÛÀ¸·Î ÀÎÇØ ½ÃÀå È®´ë¸¦ ÁÖµµÇϰí ÀÖÀ¸¸ç, ¾Æ½Ã¾ÆÅÂÆò¾çÀº ÀÇ·á¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ºü¸£°Ô ºÎ»óÇϰí ÀÖ½À´Ï´Ù. Áö¼ÓÀûÀÎ ¿¬±¸ ÅõÀÚ, Çõ½ÅÀûÀÎ Áø´Ü ¹æ¹ý, °³ÀÎÈµÈ Ä¡·á Á¢±Ù ¹æ½ÄÀº ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ȯÀÚ Ä¡·á ¹× Ä¡·á °á°ú¸¦ Çâ»ó½Ãų °ÍÀÔ´Ï´Ù.
¸ñÂ÷
¼·Ð
Á¶»ç ¹æ¹ý
- Á¤º¸ Á¶´Þ
- 2Â÷¿Í 1Â÷ µ¥ÀÌÅÍ ¹æ¹ý
- ½ÃÀå ±Ô¸ð ¿¹Ãø
- ½ÃÀå ÀüÁ¦Á¶°Ç°ú Á¦ÇÑ
ÁÖ¿ä ¿ä¾à
- ¼¼°è ½ÃÀå Àü¸Á
- °ø±Þ°ú ¼ö¿ä µ¿Ç⠺м®
- ºÎ¹®º° ±âȸ ºÐ¼®
½ÃÀå ¿ªÇаú Àü¸Á
- ½ÃÀå °³¿ä
- ½ÃÀå ±Ô¸ð
- ½ÃÀå ¿ªÇÐ
- ¼ºÀå ÃËÁø¿äÀΰú ±âȸ
- ¼ºÀå ¾ïÁ¦¿äÀΰú °úÁ¦
- PorterÀÇ Five Forces ºÐ¼®
ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ®
- Áß¿ä ¼º°ø ¿äÀÎ
- °æÀï Á¤µµ
- ÁÖ¿ä ÅõÀÚ ±âȸ
- ½ÃÀå »ýŰè
- ½ÃÀåÀÇ ¸Å·Â Áö¼ö(2024³â)
- PESTEL ºÐ¼®
- °Å½Ã°æÁ¦ ÁöÇ¥
- ¹ë·ùüÀÎ ºÐ¼®
- °¡°Ý ºÐ¼®
- »ç·Ê ¿¬±¸
- ±ÔÁ¦ »óȲ
- ƯÇ㠺м®
¸Á¸·Á¤¸ÆÆó¼âÁõ Ä¡·á ½ÃÀå ±Ô¸ð : Áúȯ À¯Çüº°&CAGR(2025-2032³â)
- ½ÃÀå °³¿ä
- ¸Á¸·Á᫐ Á¤¸Æ Æó¼â(CRVO)
- ¸Á¸·Á¤¸Æ ºÐÁö Æó¼â(BRVO)
¸Á¸·Á¤¸ÆÆó¼âÁõ Ä¡·á ½ÃÀå ±Ô¸ð : Ä¡·á À¯Çüº°&CAGR(2025-2032³â)
- ½ÃÀå °³¿ä
- Ç×VEGF
- ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵å
- ·¹ÀÌÀú Ä¡·á
¸Á¸·Á¤¸ÆÆó¼âÁõ Ä¡·á ½ÃÀå ±Ô¸ð : Åõ¾à À¯Çüº°&CAGR(2025-2032³â)
¸Á¸·Á¤¸ÆÆó¼âÁõ Ä¡·á ½ÃÀå ±Ô¸ð : ÃÖÁ¾»ç¿ëÀÚº°&CAGR(2025-2032³â)
- ½ÃÀå °³¿ä
- º´¿ø
- ¾È°ú Ŭ¸®´Ð
- ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)
- ¼Ò¸Å ¾à±¹
¸Á¸·Á¤¸ÆÆó¼âÁõ Ä¡·á ½ÃÀå ±Ô¸ð : Áö¿ªº°&CAGR(2025-2032³â)
- ºÏ¹Ì
- À¯·´
- µ¶ÀÏ
- ½ºÆäÀÎ
- ÇÁ¶û½º
- ¿µ±¹
- ÀÌÅ»¸®¾Æ
- ±âŸ À¯·´
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- Áß±¹
- Àεµ
- ÀϺ»
- Çѱ¹
- ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
- ¶óƾ¾Æ¸Þ¸®Ä«
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
- GCC ±¹°¡
- ³²¾ÆÇÁ¸®Ä«°øÈ±¹
- ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
°æÀï Á¤º¸
- ÁÖ¿ä 5°³»ç ºñ±³
- ÁÖ¿ä ±â¾÷ÀÇ ½ÃÀå Æ÷Áö¼Å´×(2024³â)
- ÁÖ¿ä ½ÃÀå ±â¾÷ÀÌ Ã¤ÅÃÇÑ Àü·«
- ÃÖ±Ù ½ÃÀå µ¿Çâ
- ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®(2024³â)
- ÁÖ¿ä ±â¾÷ °³¿ä
- ±â¾÷ »ó¼¼
- Á¦Ç° Æ÷Æ®Æú¸®¿À ºÐ¼®
- ±â¾÷ ºÎ¹®º° Á¡À¯À² ºÐ¼®
- Àü³â´ëºñ ¸ÅÃâ ºñ±³(2022-2024³â)
ÁÖ¿ä ±â¾÷ °³¿ä
- AbbVie Inc.(USA)
- Roche(Switzerland)
- Regeneron Pharmaceuticals, Inc.(USA)
- Novartis AG(Switzerland)
- Bayer AG(Germany)
- Alimera Sciences(USA)
- Aerie Pharmaceuticals, Inc.(USA)
- Kodiak Sciences Inc.(USA)
- Chugai Pharmaceutical Co., Ltd.(Japan)
- Taiwan Liposome Company, Ltd.(Taiwan)
- Graybug Vision, Inc.(USA)
- Pfizer Inc.(USA)
- IRIDEX Corporation(USA)
- Lumenis(Israel)
- Nidek Co., Ltd.(Japan)
- Annexin Pharmaceuticals AB(Sweden)
- Outlook Therapeutics, Inc.(USA)
- CalciMedica Inc.(USA)
- F. Hoffmann-La Roche AG(Switzerland)
- Samsung Bioepis(South Korea)
°á·Ð°ú Á¦¾È
LSH
Retinal Vein Occlusion Treatment Market size was valued at USD 2.43 billion in 2023 and is poised to grow from USD 2.59 billion in 2024 to USD 4.25 billion by 2032, growing at a CAGR of 6.4% during the forecast period (2025-2032).
The retinal vein occlusion (RVO) treatment market is experiencing significant growth, fueled by the rising prevalence of RVO and an aging population susceptible to this disorder. RVO, a prevalent retinal vascular issue, can lead to vision impairment if untreated. The market offers a variety of solutions, including medications, laser therapy, and surgical options, primarily focusing on enhancing blood circulation and reducing macular edema. Anti-VEGF medications are particularly favored for managing abnormal blood vessel development. Regions like North America and Europe lead in market expansion due to advanced healthcare systems, while the Asia-Pacific region is rapidly emerging, driven by increased healthcare awareness. Continuous research investment, innovative diagnostics, and personalized treatment approaches are set to further propel market growth, enhancing patient care and outcomes.
Top-down and bottom-up approaches were used to estimate and validate the size of the Retinal Vein Occlusion Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Retinal Vein Occlusion Treatment Market Segments Analysis
Global Retinal Vein Occlusion Treatment Market is segmented by Disease Type, Treatment Type, Medication Type, End-user and region. Based on Disease Type, the market is segmented into Central Retinal Vein Occlusion (CRVO) and Branch Retinal Vein Occlusion (BRVO). Based on Treatment Type, the market is segmented into Anti-VEGF, Corticosteroid Drugs and Laser Therapy. Based on Medication Type, the market is segmented into Branded and Generics. Based on End-user, the market is segmented into Hospitals, Ophthalmic Clinics, Ambulatory Surgical Centers (ASC) and Retail Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Retinal Vein Occlusion Treatment Market
The market for retinal vein occlusion treatment is propelled by various influential factors, including the increasing prevalence of eye disorders worldwide, a rising elderly demographic, enhanced comprehension of ocular conditions, and the expansion of healthcare infrastructures. Additionally, technological innovations and the development of new therapies significantly boost market growth. The existence of a strong drug pipeline, along with recent drug approvals, plays a vital role in this upward trend. As cases of retinal vein occlusion continue to surge and research on effective treatments intensifies, there is potential for significant market expansion, opening avenues for the adoption of cutting-edge therapeutic solutions for this condition.
Restraints in the Retinal Vein Occlusion Treatment Market
The Retinal Vein Occlusion Treatment market encounters a significant challenge due to a lack of long-term clinical evidence. The effectiveness and safety of various treatment options compared to conventional therapies require more comprehensive evaluation. This uncertainty can hinder the adoption of newer therapies, as both healthcare professionals and patients may be hesitant to embrace treatments that lack robust, long-term studies. Furthermore, the dependence on existing treatments may continue as practitioners seek reassurance about the outcomes of emerging options. Consequently, addressing this restraint is essential for promoting growth and acceptance within the Retinal Vein Occlusion Treatment market.
Market Trends of the Retinal Vein Occlusion Treatment Market
The Retinal Vein Occlusion Treatment market is witnessing significant growth, primarily fueled by the rising prevalence of the condition among the aging population. As more individuals enter older age brackets, the incidence of retinal vein occlusion is expected to increase, necessitating innovative and effective treatment options. This trend is prompting healthcare providers and pharmaceutical companies to develop advanced therapies, including anti-VEGF injections and laser treatments, to cater to the growing patient demographic. As awareness and diagnosis improve, coupled with advancements in treatment modalities, the market is set to expand further, offering lucrative opportunities for stakeholders in the ophthalmology sector.
Table of Contents
Introduction
- Objectives of the Study
- Scope of the Report
- Definitions
Research Methodology
- Information Procurement
- Secondary & Primary Data Methods
- Market Size Estimation
- Market Assumptions & Limitations
Executive Summary
- Global Market Outlook
- Supply & Demand Trend Analysis
- Segmental Opportunity Analysis
Market Dynamics & Outlook
- Market Overview
- Market Size
- Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
- Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers
Key Market Insights
- Key Success Factors
- Degree of Competition
- Top Investment Pockets
- Market Ecosystem
- Market Attractiveness Index, 2024
- PESTEL Analysis
- Macro-Economic Indicators
- Value Chain Analysis
- Pricing Analysis
- Case Studies
- Regulatory Landscape
- Patent Analysis
Global Retinal Vein Occlusion Treatment Market Size by Disease Type & CAGR (2025-2032)
- Market Overview
- Central Retinal Vein Occlusion (CRVO)
- Branch Retinal Vein Occlusion (BRVO)
Global Retinal Vein Occlusion Treatment Market Size by Treatment Type & CAGR (2025-2032)
- Market Overview
- Anti-VEGF
- Corticosteroid Drugs
- Laser Therapy
Global Retinal Vein Occlusion Treatment Market Size by Medication Type & CAGR (2025-2032)
- Market Overview
- Branded
- Generics
Global Retinal Vein Occlusion Treatment Market Size by End-user & CAGR (2025-2032)
- Market Overview
- Hospitals
- Ophthalmic Clinics
- Ambulatory Surgical Centers (ASC)
- Retail Pharmacies
Global Retinal Vein Occlusion Treatment Market Size & CAGR (2025-2032)
- North America (Disease Type, Treatment Type, Medication Type, End-user)
- Europe (Disease Type, Treatment Type, Medication Type, End-user)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Disease Type, Treatment Type, Medication Type, End-user)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Disease Type, Treatment Type, Medication Type, End-user)
- Brazil
- Rest of Latin America
- Middle East & Africa (Disease Type, Treatment Type, Medication Type, End-user)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2024
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2024
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)
Key Company Profiles
- AbbVie Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Roche (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Regeneron Pharmaceuticals, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Alimera Sciences (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Aerie Pharmaceuticals, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Kodiak Sciences Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Chugai Pharmaceutical Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Taiwan Liposome Company, Ltd. (Taiwan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Graybug Vision, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- IRIDEX Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Lumenis (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Nidek Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Annexin Pharmaceuticals AB (Sweden)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Outlook Therapeutics, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- CalciMedica Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- F. Hoffmann-La Roche AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Samsung Bioepis (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Conclusion & Recommendations